MR-based Models for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)

Conditions

Hypertension, Portal

Keywords

clinically significant portal hypertension, hepatic venous pressure gradient, MR imaging

Brief summary

Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥ 10mmHg) is invasive and therefore not suitable for routine clinical practice. This is a multi-center diagnostic trial conducted at high-volume liver centres designed to determine the accuracy of MR-based models (investigational technology) for noninvasive detection of a CSPH in patients with cirrhosis. Transjugular HVPG measurement by means of catheterization of a hepatic vein with a balloon catheter is the gold-standard method to assess the presence of CSPH.

Detailed description

Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations in cirrhosis. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG≥ 10mmHg) is invasive and therefore not suitable for routine clinical practice. This is a multi-center diagnostic trial conducted at high-volume liver centres (Zhongda Hospital, Medical School of Southeast University; Affiliated Lishui Hospital of Zhejiang University; Shandong Provincial Hospital affiliated to Shandong University; Beijing 302 Hospital; Xingtai People's Hospital; Shunde Hospital, Southern Medical University; The First Hospital of Zhengzhou University; Shanghai Public Health Clinical Center, Fudan University; The First Hospital of Lanzhou University; Nanfang Hospital of Southern Medical University; Ankara University School of Medicine) designed to determine the accuracy of MR-based models (investigational technology) for noninvasive detection of a CSPH in patients with cirrhosis. Transjugular HVPG measurement by means of catheterization of a hepatic vein with a balloon catheter is the gold-standard method to assess the presence of CSPH.

Chengyan Wang, Yifei Huang, Changchun Liu, Fuquan Liu, Xumei Hu et al. (13 authors)

Radiology2023-01-3123 citations

10.1148/radiol.221648

Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study.

Liu Y, Tang T, Örmeci N, Huang Y, Wang J, Li X, Li Z, An W, Liu D, Zhang C, Liu C, Liu J, Liu C, Wang G, Mosconi C, Cappelli A, Bruno A, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Li L, Zhang H, Kang N, Xu D, He R, Wang Y, Bu Y, Gu Y, Ju S, Golfieri R, Qi X.

2021-09-303 citations

10.14218/jcth.2021.00177

Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis.

Liu Y, Ning Z, Örmeci N, An W, Yu Q, Han K, Huang Y, Liu D, Liu F, Li Z, Ding H, Luo H, Zuo C, Liu C, Wang J, Zhang C, Ji J, Wang W, Wang Z, Wang W, Yuan M, Li L, Zhao Z, Wang G, Li M, Liu Q, Lei J, Liu C, Tang T, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Liu Z, Teng G, Chen Y, Hou J, Li X, He X, Dong J, Tian J, Liang P, Ju S, Zhang Y, Qi X.

2020-03-2141 citations

10.1016/j.cgh.2020.03.034

Interventions

PROCEDURETransjugular HVPG measurement

By means of catheterization of a hepatic vein with a balloon catheter.

PROCEDUREMR imaging

MR images for the post-processing analysis

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

No

Inclusion criteria

* Age 18-75 years * With written informed consent * Confirmed liver cirrhosis based on liver biopsy or clinical findings * Scheduled to undergo clinically-indicated transjugular HVPG measurement by means of catheterization of a hepatic vein with a balloon catheter * Has undergone\> MR imaging within 14 days to hepatic vein catheterization * No hepatic-portal vein interventional therapy between MR imaging and hepatic vein catheterization

Exclusion criteria

* A contraindication to MR imaging, in particular pacemakers or implantable defibrillators, cochlear implants, neurosurgical clips, intra-orbital or brain metallic foreign bodies, endo prothesis since less than 4 weeks or osteosynthesis material since less than 6 weeks * Unable to comply with breathing or other imaging related instructions resulting in inability to obtain diagnostic quality MR imaging studies * Contraindication to the injection of contrast agent: pregnancy, lactation, history of allergic reaction to contrast agent injection. * Prior transjugular intrahepatic portosystem stent-shunt surgery * Prior devascularization operation * Has received a liver transplant * Any active, serious, life-threatening disease

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic Performance of MR-based Models	1 day	Accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of MR-based models for noninvasive detection of CSPH when compared to HVPG as the reference standard.

Countries

China, Turkey (Türkiye)

Outcome results

None listed